Peripheral Artery Disease Program
Peripheral Artery Disease
Pre-clinicalActive
Key Facts
About Elixir Medical
Elixir Medical is an early-stage, private medical device company targeting the massive and underserved cardiovascular disease market. The company is developing transformative platforms for percutaneous coronary intervention (PCI) and peripheral interventions, aiming to address significant unmet needs such as high rates of adverse events and disease recurrence. While still in a pre-revenue, pre-clinical/development stage, Elixir positions itself as a disruptor seeking to reshape vascular medicine for decades to come by tackling problems where others have given up.
View full company profileTherapeutic Areas
Other Peripheral Artery Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Aperta NSE™ PTA | Nipro Medical | Commercial |
| JTV-263 | Akros Pharma | Phase1 |
| Luminor DCB | iVascularU | Post-Market |
| iVolution pro Stent | iVascularU | Post-Market |
| FGF-1 | Zhittya Genesis Medicine | Phase 2 |
| ChampioNIR | Medinol | Investigational |
| Peripheral Stent | Advanced Biomed | Approved |
| Ranger DCB | Boston Scientific | Pivotal Trial |